Molecular profiling of head and neck squamous cell carcinoma

Head and Neck

Volumn 38, Issue , 2016, Pages E1625-E1638

  Feldman, Rebecca ^a   Gatalica, Zoran ^a   Knezetic, Joseph ^b   Reddy, Sandeep ^a   Nathan, Cherie Ann ^c   Javadi, Nader ^d   Teknos, Theodoros ^e  

^a CARIS LIFE SCIENCES   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

^d Hope Health Center   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

biomarkers; DNA sequencing; head and neck squamous cell carcinoma; molecular profiling; protein expression

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH1 RECEPTOR; OSTEONECTIN; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; PROTEIN GNAQ; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN SMARCB1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE QUALITY; HUMAN; HYPOPHARYNX CANCER; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERY ELDERLY; WART VIRUS; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGRAMMED CELL DEATH 1 RECEPTOR; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84949844349     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.24290     Document Type: Article

References (58)

1. Leemans CR, Braakhuis BJ, Brakenhoff RH,. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11: 9-22.
2. Chaturvedi AK, Engels EA, Pfeiffer RM, et al., Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
3. Stegh AH,. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Expert Opin Ther Targets 2012; 16: 67-83.
4. National Comprehensive Cancer Network. Head and Neck Cancers, version 2.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/head-and-neck.pdf. Accessed August 27, 2014.
5. Colevas AD,. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-2652.
6. Szabó B, Nelhubel GA, Kárpáti A, Kenessey I, Jóri B, Szekely C,. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas. Oral Oncol 2011; 47: 487-496.
7. Vermorken JB, Peyrade F, Krauss J, et al., Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol 2014; 25: 682-688.
8. Licitra L, Mesia R, Rivera F, et al., Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011; 22: 1078-1087.
9. Lui VW, Hedberg ML, Li H, et al., Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 2013; 3: 761-769.
10. Janku F, Tsimberidou AM, Garrido-Laguna I, et al., PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10: 558-565.
11. Castel P, Juric D, Won H, et al., Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure. Presented at the American Association for Cancer Research Annual Meeting 2014; April 5-9, 2014; San Diego, CA. Abstract LB-327.
12. Lyford-Pike S, Peng S, Young GD, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-1741.
13. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al., Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
14. Tsimberidou AM, Wen S, Hong DS, et al., Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res 2014; 20: 4827-4836.
15. National Comprehensive Cancer Network. The NCCN Biomarkers Compendium (NCCN Compendium). Available at: http://www.nccn.org/professionals/biomarkers/content/. Accessed June 1, 2015.
16. Millis SZ, Bryant D, Basu G, et al., Molecular profiling of infiltrating urothelial carcinoma of both bladder and non-bladder origin. Clin Genitourin Cancer 2015; 13: e37-e49.
17. Mountzios G, Rampias T, Psyrri A,. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol 2014; 25: 1889-1900.
18. Agrawal N, Frederick MJ, Pickering CR, et al., Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
19. Stransky N, Egloff AM, Tward AD, et al., The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-1160.
20. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576-582.
21. Sève P, Mackey J, Isaac S, et al., Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4: 2001-2007.
22. Kulkarni SA, Hicks DG, Watroba NL, et al., TLE3 as a candidate biomarker of response to taxane therapy. Breast Cancer Res 2009; 11: R17.
23. Qiu LX, Tang QY, Bai JL, et al., Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008; 123: 2384-2389.
24. Zhao LP, Xue C, Zhang JW, et al., Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer 2012; 31: 476-483.
25. Vilmar AC, Santoni-Rugiu E, Sørensen JB,. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010; 21: 1817-1824.
26. Cohen EE,. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2659-2665.
27. Licitra L, Störkel S, Kerr KM, et al., Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 2013; 49: 1161-1168.
28. Munoz M, Henderson M, Haber M, Norris M,. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007; 59: 752-757.
29. Gottesman MM, Pastan I,. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
30. Thomas H, Coley HM,. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10: 159-165.
31. Gilbert J, Dang T, Cmelak A, et al., Single agent irinotecan for the treatment of metastatic or recurrent squamous carcinoma of the head and neck (SCCHN). Clin Med Oncol 2007; 1: 59-63.
32. Desai N, Trieu V, Damascelli B, Soon-Shiong P,. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2: 59-64.
33. Lacroix L, Post SF, Valent A, et al., MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One 2014; 9: e84319.
34. Spiegl-Kreinecker S, Pirker C, Filipits M, et al., O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 2010; 12: 28-36.
35. Gong W, Zhang X, Wu J, et al., RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 2012; 75: 374-380.
36. Hochhauser D, Glynne-Jones R, Potter V, et al., A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther 2013; 12: 809-818.
37. Catimel G, Vermorken JB, Clavel M, et al., A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547.
38. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H,. Gemcitabine in the treatment of advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2005; 17: 425-429.
39. Khan AJ, King BL, Smith BD, et al., Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 2002; 8: 540-548.
40. Falchook GS, Lippman SM, Bastida CC, Kurzrock R,. Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck 2014; 36: E25-E27.
41. Del Campo JM, Hitt R, Sebastian P, et al., Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011; 105: 618-627.
42. Chung CH,. PIK3CA: the most common "targetable" genetic alteration in head and neck cancer-who might benefit? American Society of Clinical Oncology 2015 meeting. Chicago, IL.
43. Fruman DA, Rommel C,. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156.
44. Janku F, Hong DS, Fu S, et al., Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep 2014; 6: 377-387.
45. Juric D, Castel P, Griffith M, et al., Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 2015; 518: 240-244.
46. Rampias T, Giagini A, Siolos S, et al., RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res 2014; 20: 2933-2946.
47. Wang Z, Martin D, Molinolo AA, et al., mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014; 106: 215.
48. Hyman DM, Snyder AE, Carvajal RD, et al., Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer Chemother Pharmacol 2015; 75: 747-755.
49. Braun MS, Richman SD, Quirke P, et al., Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26: 2690-2698.
50. Desai N, Trieu V, Yao Z, et al., Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006; 12: 1317-1324.
51. Shacham-Shmueli E, Beny A, Geva R, Blachar A, Figer A, Aderka D,. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine? J Clin Oncol 2011; 29: e262-e265.
52. Seiwert TY, Zuo Z, Keck MK, et al., Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 2015; 21: 632-641.
53. Walter V, Yin X, Wilkerson MD, et al., Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One 2013; 8: e56823.
54. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al., Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013; 14: 697-710.
55. Vermorken JB, Psyrri A, Mesía R, et al., Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol 2014; 25: 801-807.
56. Burtness B,. Activity of cetuximab (C) in head and neck squamous cell carcinoma (HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C. American Society of Clinical Oncology 2013 meeting. Chicago, IL.
57. Ganesan P, Ali SM, Wang K, et al., Epidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapy. J Clin Oncol 2014. [Epub ahead of print].
58. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.